Slow start to the year as expected

Liked this post? Share with others!

Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o   Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso   New Pharmaceuticals products deliver strong growth – headwinds in Chinao   Consumer Health continues to growEBITDA before special items: 4.471 billion euros (minus 14.9 percent)o   Glyphosate and inflation weigh on earningso   Pharmaceuticals maintains high R&D investmentCore earnings per share at 2.95 euros (minus 16.4 percent)Net income at 2.178 billion eurosFree cash flow at minus 4.102 billion eurosGroup outlook confirmed – target attainment at lower end of guidance Leverkusen…
Read More

Subscribe to our newsletter

Collect visitor’s submissions and store it directly in your Elementor account, or integrate your favorite marketing & CRM tools.

Do you want to boost your business today?

This is your chance to invite visitors to contact you. Tell them you’ll be happy to answer all their questions as soon as possible.

Learn how we helped 100 top brands gain success